Compare VOR & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOR | OCSL |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2007 |
| Metric | VOR | OCSL |
|---|---|---|
| Price | $19.18 | $11.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $39.00 | $12.13 |
| AVG Volume (30 Days) | ★ 636.5K | 367.7K |
| Earning Date | 10-30-2026 | 11-17-2026 |
| Dividend Yield | N/A | ★ 10.48% |
| EPS Growth | N/A | ★ 17.95 |
| EPS | N/A | ★ 0.46 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.27 |
| P/E Ratio | ★ N/A | $25.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.21 | $10.63 |
| 52 Week High | $26.00 | $13.91 |
| Indicator | VOR | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 40.56 |
| Support Level | $17.62 | $11.71 |
| Resistance Level | $20.11 | $12.35 |
| Average True Range (ATR) | 1.29 | 0.32 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 44.48 | 10.00 |
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.